---
title: "Tempus AI's $1.9 billion Personalis buy heads to a Nov 30 vote, paid in Tempus stock with up to half in cash"
description: "The $1.9 billion Personalis deal goes to a shareholder vote on November 30 with regulatory review already closed, and the filing shows Tempus pays in its own stock with up to half in cash, against $854 million on its balance sheet."
publisher: "The Inference"
section: "Deals"
published: 2026-11-16T22:07:30.589Z
modified: 2026-11-16T22:07:30.589Z
canonical: https://theinference.org/article/tempus-ai-s-1-9-billion-personalis-buy-heads-to-a-nov-30-vote-paid-in-tempus-stock-with-up-to-half-in-cash
language: en
keywords: "Tempus AI, Personalis, Deals, Health, Genomics"
---

# Tempus AI's $1.9 billion Personalis buy heads to a Nov 30 vote, paid in Tempus stock with up to half in cash

> The $1.9 billion Personalis deal goes to a shareholder vote on November 30 with regulatory review already closed, and the filing shows Tempus pays in its own stock with up to half in cash, against $854 million on its balance sheet.

Personalis shareholders vote on November 30, 2026, on the $1.9 billion sale of their cancer-testing company to [Tempus AI](https://theinference.org/markets/companies/tempus-ai), the Chicago diagnostics and clinical-data firm, and [the filing behind that vote](https://www.sec.gov/Archives/edgar/data/1527753/000119312526456628/d22735d425.htm) shows exactly who writes the check [2]. Regulatory review is already complete, Tempus told its [Q3 earnings call](https://www.theglobeandmail.com/investing/markets/stocks/TEM/pressreleases/8846190/tempus-ai-earnings-call-highlights-growth-and-scale/) on November 15 [2]. The consideration is Tempus stock, with up to half payable in cash at Tempus's election, decided as late as three business days before closing [3].

## The maximum cash election tops the bank account

Half of the $1,920 million equity value is about $960 million in cash, against $854 million of cash and marketable securities Tempus held at September 30 [2]. Even the maximum cash election tops the balance sheet, and Personalis brings $213 million of its own cash, trimming the net enterprise cost to $1,709 million [3]. Management told the call that operating cash flow and existing liquidity should fund both growth and the acquisition [2], but the arithmetic leaves little slack, and Tempus has burned cash in most recent quarters.

*Chart: **Tempus burned operating cash in eight of the last ten quarters** Column chart of Tempus AI's quarterly operating cash flow from Q2 2024 to Q3 2026, negative in eight of ten quarters, with Q3 2026 the first positive quarter since Q2 2025*

*USD millions; quarterly operating cash flow as reported in Tempus AI's SEC filings, retrieved 16 November 2026. Bars below zero are cash used in operations. Q3 2026 is the first positive quarter since Q2 2025. [4]*

## The collar moves the price risk onto Tempus holders

Below a $48.42 floor, the exchange ratio locks at 0.3356, so Tempus issues more shares as its stock falls; Personalis can walk away below $46.00 [3]. Tempus traded below the lower floor on announcement day [3]. Stock consideration means roughly 14.8 percent pro forma dilution [3], and a fixed $16.25 per share goes to Personalis holders either way. Tempus also pays at 15.2x EV to forward revenue, about 2.4 times the diagnostic-deal median its own bankers cited [3], and it is buying a business that loses money on every MRD test, with only 15 percent of its sales force selling the assay [2].

*Chart: **The $1.92 billion price is more than twice Tempus's cash pile** Bars comparing Tempus cash on hand, maximum cash portion of the Personalis consideration and the full equity value of the deal*

*USD millions. Cash and marketable securities per Tempus Q3 2026 earnings call; equity value and cash-election mechanics per Personalis merger 425 filing. The maximum cash figure is derived as 50 percent of the $1,920 million equity value. [2][3]*

## Tempus's own share price now sets the price it pays

The proxy states whether Tempus elects cash, and whether the 15-day VWAP holds above $48.42 [2]. Tempus [raised 2026 revenue guidance](https://theinference.org/article/tempus-ai-beat-q3-but-80-million-of-2027-growth-rides-on-a-december-31-medicare-deadline) to about $1.60 billion with roughly $65 million of adjusted EBITDA [2], so the quarter is strong; the question is whether it can carry a money-losing target without printing shares at the bottom of a collar it wrote for itself. Deep dive in below to learn more.

## Takeaway

The cash half of the $1.92 billion price is about $960 million, more than the $854 million of cash and securities Tempus held at September 30, and the collar means a falling Tempus share price buys Personalis holders more Tempus stock.

## Sources

2. [Tipranks via The Globe and Mail, Tempus AI Earnings Call Highlights Growth and Scale, 15 November 2026](https://www.theglobeandmail.com/investing/markets/stocks/TEM/pressreleases/8846190/tempus-ai-earnings-call-highlights-growth-and-scale/)
3. [Personalis, Inc. Rule 425 investor presentation filed with the SEC, 12 November 2026](https://www.sec.gov/Archives/edgar/data/1527753/000119312526456628/d22735d425.htm)
4. [Tempus AI, quarterly figures from its SEC filings, retrieved 16 November 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001717115)


---

Tempus AI's $1.9 billion Personalis buy heads to a Nov 30 vote, paid in Tempus stock with up to half in cash — The Inference. Canonical: https://theinference.org/article/tempus-ai-s-1-9-billion-personalis-buy-heads-to-a-nov-30-vote-paid-in-tempus-stock-with-up-to-half-in-cash
